Phillips Medisize targets formulation-device risk as inhaled therapies grow more complex
Inhalers are getting smarter, but complexity can backfire. Phillips Medisize is betting DPI success starts with patient-centric design.
Can Aptar Pharma help solve the bioequivalence challenge in next-generation inhalers?
Greener inhalers need more than lower-carbon chemistry. Aptar Pharma’s FDA-backed work tests the science regulators may need.